Pages that link to "Q33236663"

The following pages link to Inhibition of the mammalian target of rapamycin (mTOR) by rapamycin increases chemosensitivity of CaSki cells to paclitaxel (Q33236663):

Displaying 32 items.

• Colocalized delivery of rapamycin and paclitaxel to tumors enhances synergistic targeting of the PI3K/Akt/mTOR pathway (Q30583249) (← links)
• Selenium enrichment of broccoli sprout extract increases chemosensitivity and apoptosis of LNCaP prostate cancer cells (Q30924425) (← links)
• AICAR inhibits proliferation and induced S-phase arrest, and promotes apoptosis in CaSki cells (Q33306763) (← links)
• Safety and pharmacokinetics of paclitaxel and the oral mTOR inhibitor everolimus in advanced solid tumours. (Q33382682) (← links)
• A phase I study of temsirolimus plus carboplatin plus paclitaxel for patients with recurrent or metastatic (R/M) head and neck squamous cell cancer (HNSCC). (Q33401499) (← links)
• A phase-1b study of everolimus plus paclitaxel in patients with small-cell lung cancer (Q33409908) (← links)
• Rapamycin potentiates the effects of paclitaxel in endometrial cancer cells through inhibition of cell proliferation and induction of apoptosis (Q33638550) (← links)
• SPAG5 upregulation predicts poor prognosis in cervical cancer patients and alters sensitivity to taxol treatment via the mTOR signaling pathway (Q33720115) (← links)
• Contextualization of drug-mediator relations using evidence networks (Q33802232) (← links)
• Phase 1 and pharmacokinetic study of everolimus, a mammalian target of rapamycin inhibitor, in combination with docetaxel for recurrent/refractory nonsmall cell lung cancer. (Q34130665) (← links)
• Targeting the PI3K/Akt/mTOR pathway in hepatocellular carcinoma. (Q34632966) (← links)
• Mammalian target of rapamycin: hitting the bull's-eye for neurological disorders (Q35157985) (← links)
• Paclitaxel resistance is associated with switch from apoptotic to autophagic cell death in MCF-7 breast cancer cells (Q35723911) (← links)
• Metformin potentiates the effects of paclitaxel in endometrial cancer cells through inhibition of cell proliferation and modulation of the mTOR pathway (Q35877999) (← links)
• Vascular endothelial growth factor A as predictive marker for mTOR inhibition in relapsing high-grade serous ovarian cancer (Q35992948) (← links)
• Potential impact of mTOR inhibitors on cervical squamous cell carcinoma: A systematic review (Q36206239) (← links)
• Antitumor activity of Triolimus: a novel multidrug-loaded micelle containing Paclitaxel, Rapamycin, and 17-AAG. (Q36312850) (← links)
• Enhanced Antitumor Activity with Combining Effect of mTOR Inhibition and Microtubule Stabilization in Hepatocellular Carcinoma (Q36663932) (← links)
• Reduced BCL2 and CCND1 mRNA expression in human cervical cancer HeLa cells treated with a combination of everolimus and paclitaxel. (Q36792877) (← links)
• Evaluation of the tubulin-bound paclitaxel conformation: synthesis, biology, and SAR studies of C-4 to C-3' bridged paclitaxel analogues (Q36979015) (← links)
• Role of activating transcription factor 3 on TAp73 stability and apoptosis in paclitaxel-treated cervical cancer cells (Q37198034) (← links)
• A phase 1 study of weekly everolimus (RAD001) in combination with docetaxel in patients with metastatic breast cancer (Q37483253) (← links)
• Fisetin Enhances Chemotherapeutic Effect of Cabazitaxel against Human Prostate Cancer Cells (Q38739235) (← links)
• Combined treatment strategies for microtubule stabilizing agent-resistant tumors (Q38908225) (← links)
• Potential biomarkers for paclitaxel sensitivity in hypopharynx cancer cell (Q39051376) (← links)
• Proteomic analysis reveals tanshinone IIA enhances apoptosis of advanced cervix carcinoma CaSki cells through mitochondria intrinsic and endoplasmic reticulum stress pathways (Q39069268) (← links)
• A gene signature-based approach identifies thioridazine as an inhibitor of phosphatidylinositol-3'-kinase (PI3K)/AKT pathway in ovarian cancer cells. (Q39638086) (← links)
• Synergistic effect of rapamycin and cisplatin in endometrial cancer cells (Q39844530) (← links)
• Rapamycin and curcumin induce apoptosis in primary resting B chronic lymphocytic leukemia cells. (Q44638649) (← links)
• Phase I clinical trial of temsirolimus and vinorelbine in advanced solid tumors (Q46342083) (← links)
• Phase 1b study of the mammalian target of rapamycin inhibitor sirolimus in combination with nanoparticle albumin-bound paclitaxel in patients with advanced solid tumors. (Q54292748) (← links)
• MicroRNA-495 Confers Increased Sensitivity to Chemotherapeutic Agents in Gastric Cancer via the Mammalian Target of Rapamycin (mTOR) Signaling Pathway by Interacting with Human Epidermal Growth Factor Receptor 2 (ERBB2) (Q58700608) (← links)